Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

While Singapore has remained free of avian influenza, the risks persists. Read more at straitstimes.com. Read more at ...